Article Listing - AstraZeneca profit leaps 30% but firm admits thin pipeline
OPTIMIZATION OF GLOBAL R&D STRATEGY
20 April 1992
Because pharmaceutical development times contain, of necessity, prescribed periods which are of similar duration for competing innovator companies (eg long-term...
EC PHARMA MARKET LURCHES TO COMPLETION
20 April 1992
The complex issue of creating a unified drug marketing approval regime in the European Comm-unity internal market is outlined in...
MERGER DENIALS BY CIBA-GEIGY
20 April 1992
Alex Krauer, managing director of the Swiss chemical and pharmaceutical concern, Ciba-Geigy, has denied that his company could be about...
SLIGHT RISE IN UCB PRETAX PROFITS
20 April 1992
The Belgian UCB chemical and pharmaceutical group UCB announced a slight rise of 1% in pretax ordinary profits for 1991...
US AIDS MARKET FORECASTS TO 1998
20 April 1992
The US market for products to diagnose, monitor and treat AIDS will grow from close to $300 million in 1991...
US SENATE PASSES DEBARMENT BILL
20 April 1992
The US Senate passed HR 2454, the Generic Drug Enforcement Act, with some amendments, just before Congress broke for the...
DRUG REVIEW PLAN SETS FOUR INITIATIVES
20 April 1992
Four initiatives are to be implemented by the US Food and Drug Administration to speed access to new drugs and...
STOCK MARKET COMMENTARY: NEW YORK
20 April 1992
NEW YORK: having lost heavily for the first two reporting days, the Dow Jones failed to close the week...
CELTRIX' THOMAS DAVIS
20 April 1992
Thomas Davis is elected to the board of directors at Celtrix Pharmaceuticals.
CHINESE ARTHRITIS REMEDY UNDER TEST
20 April 1992
Researchers at the University of Texas Southwestern Medical Center in the USA have applied to the US Food and Drug...
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
